Status: Active
R3 Vascular
- Status Current
- Sector Peripheral Vascular
- Year Invested 2020
- HQ Mountain View, CA, United States & Munich, Germany
- Clinical Operations Austria, Italy, Canada
- Lead Partners Frederik Groenewegen
Website www.r3vascular.com/
Related News
Bioresorbable Scaffold Technology for Treatment of Peripheral Vascular Disease
R3 has developed a novel technology platform of fully bioresorbable vascular scaffolds with a sirolimus coating for treatment of Peripheral Artery Disease (PAD). The R3 Vascular platform combines the best of both worlds of below-the-knee (BTK) therapy, designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory result of sirolimus, but ‘disappearing’ over time as the vessel heals.